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Abstract
In this work, a first-order autoregressive hidden Markov model (AR(1)HMM) is pro-
posed. It is one of the suitable models to characterize a marker of breast cancer disease
progression essentially the progression that follows from a reaction to a treatment or
caused by natural developments. The model supposes we have observations that increase
or decrease with relation to a hidden phenomenon. We would like to discover if the
information about those observations can let us learn about the progression of the phe-
nomenon and permit us to evaluate the transition between its states (supposed discrete
here). The hidden states governed by the Markovian process would be the disease stages,
and the marker observations would be the depending observations. The parameters of the
autoregressive model are selected at the first level according to a Markov process, and at
the second level, the next observation is generated from a standard autoregressive model
of first order (unlike other models considering the successive observations are indepen-
dents). A Markov Chain Monte Carlo (MCMC) method is used for the parameter estima-
tion, where we develop the posterior density for each parameter and we use a joint
estimation of the hidden states or block update of the states.
Keywords: autoregressive hidden Markov model, breast cancer progression marker,
Gibbs sampler, hidden states joint estimation, Markov Chain Monte Carlo
1. Introduction
The main motivation behind this work is to characterize progression in breast cancer. In fact,
disease progression cannot be assessed correctly without the use of biomarkers, which would
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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effectively monitor the evolution of the patient health state, and this is the case for breast cancer.
The major challenge in this matter for researchers and clinicians is to unravel the stage of the
disease, so as to tailor the treatment for each patient and to monitor the response of a patient to a
treatment.
Currently, studies have shown that there is a correlation between the levels of certain markers
such as cancer antigen CA15-3, carcinoembryonic antigen (CEA), and serum HER2 Neu with
the stage of the disease [1]. This gives an opportunity of using a hidden Markov model (HMM)
to predict the stage of the disease based on biomarker data and to address the effectiveness of
the treatments in their influence on the transition of the cancer from one state to another. In
HMM, we have two constituents: the Markovian hidden process suitable to represent the
breast cancer stage and the observation process given by the biomarker data. By the way, we
can learn about the disease transition rates and how it progresses from primary breast cancer
to advanced cancer stage, for example.
Indeed, HMM is a useful tool for tackling numerous concrete problems in many fields but some
possible applications of HMM are in speech processing [2], in biology [3], in disease progres-
sion [4], in economics [5, 6], and in gene expression [7]. For a complete review of HMM, the
reader is referred to Zucchini and MacDonald [8], in which properties and definitions of HMM
are presented in a plausible way with both classical estimation by maximum likelihood method
and expectation maximization (EM) algorithm and the new Bayesian inference is addressed.
The model we consider here is a variation of the regular hiddenMarkovmodel, since we will use
extensions to incorporate dependence among successive observations, suggesting autoregressive
dependence among continuous observations. Consequently, we have relaxed the conditional
independence assumption from a standard HMM, because we would like to add some dynamics
to the patient disease progression and because in reality the current patient biomarker observa-
tion is dependent on the past one. In fact, the autoregressive assumption in HMM has shown its
advantage over regular HMM that cannot catch the strong dependence between successive
observations (e.g., Ref. [9]). A similar model to ours can be found in Ref. [10]. This kind of
models, which were first proposed in Ref. [11] to describe econometrics time series, is generali-
zation of both HMM and autoregressive models, will be effective in representing multiple
heterogeneous dynamics such as the disease progression dynamics, and can be even generalized
to a regime-switching ARMAmodels such as in Ref. [12].
Moreover, Our model can also be viewed as an extension of the multivariate double-chain
Markov model (DCMM) developed by Ref. [13], where there are two discrete Markov chains
of first order: the first Markov chain is observed and the second one is hidden. In contrast to
this DCMM, our multivariate first-order autoregressive hidden Markov model (MAR(1)HMM)
will lead to continuous observations, where each observation conditional on the hidden pro-
cess will depend on the previous observation according to an autoregressive process of first
order. This dynamic is promising for continuous observed disease biomarkers.
Parameter estimation is very challenging for HMM family models since the likelihood is not
available in a closed form most of the time. Thus, we call for a Markov Chain Monte Carlo
(MCMC) procedure instead of a maximum likelihood-based approach. This choice rises from
the fact that the Bayesian analysis uses prior knowledge about the process being measured,
Bayesian Inference148
and it allows direct probability statements and an approximation of posterior distributions for
the parameters. Instead in the maximum likelihood approach, we cannot have declared prior
or have exact distribution for the parameters when the likelihood is untractable or when we
have missing data (e.g., Refs. [14–16]).
Since the realization of HMM includes two separate entities: the parameters and the hidden
states, the Bayesian computation is carried out after augmenting the likelihood by the missing
hidden states [17]. The hidden states are sampled using a Gibbs sampler adopting a joint estima-
tion of the hidden states or block update of the states (instead of a single update of each state
separately) by means of a forward filtering/backward smoothing algorithm. Given the hidden
states, we can compute the autoregressive parameters and the transition probabilities of the
Markov chain by Gibbs sampler from their posterior densities after specifying conjugate priors
for the parameters. Hence, the MCMC algorithm will alternate between simulating the hidden
states and the parameters. Finally, we can obtain posteriors statistics such as the means, standard
deviations and confidence intervals after assessing the convergence of the MCMC algorithm.
This chapter is organized as follows: after a preliminary on HMM, a description of the model is
given in Section 3. In Section 4, we will give the Bayesian estimation of the parameters and the
hidden states and provide the details of the MCMC algorithm, before presenting the results of
a simulation studies in Section 5 and we will finish by a conclusion.
2. Preliminary
Since the model suggested is of the HMM type, we will describe HMM in more detail: an
HMM is a stochastic process Xt ,Ytf g
T
t¼0, where Xtf g
T
t¼0 is a hidden Markov chain
(unobservable) and Ytf g
T
t¼0 is a sequence of observable independent random variables such
that Yt depends only on Xt for the time t = 0,1,…T. Here the process Xtf g
T
t¼0 evolves indepen-
dently of Ytf g
T
t¼0 and is supposed to be a homogeneous finite Markov chain with probability
transition matrix Π of dimension a  a, where a indicates the number of the hidden states and
Π0 = (Π01,…,Π0a) is the initial state distribution.
We denote the probability density function of Yt = yt given Xt = k for k ∈ {1,…, a} with Pxtðyt,θkÞ,
where θk refers to the parameters of P when Xt = k. We suppose further that the processes Yt|Xt
and Yt0|Xt0 are independent for t 6¼ t
0. Let Θ = (θ1,…, θa) and θ = (Π0, Π, Θ), and then, the HMM
can be described as follows: First, the likelihood of the observations and the hidden states can be
decomposed to Pðy0,…, yT , x0,…, xT ,θÞ ¼ Pðy0,…, yT jx0,…, xT ,θÞPðx0,…, xT ,θÞ: Since Xtf g
T
t¼0
is a Markov chain, Pðx0,…, xT ,θÞ ¼ Π0ðx0Þ
YT
t¼1
Πðxtjxt1Þ. Under the conditional independence of
the observations given the hidden states, Pðy0,…, yT jx0,…, xT ,θÞ ¼ Px0ðy0jθx0Þ
YT
t¼1
PxtðytjθxtÞ.
Consequently, the likelihood function for the hidden states and the observations is given by
Pðy0, y1,…, yT , x0, x1,…, xT ,θÞ ¼ Πðx0ÞPx0ðy0jθx0Þ
YT
t¼0
Πðxtjxt1ÞPxtðytjθxtÞ.
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3. Model description and specification
The MAR(1)HMMmodel we consider in this work is a hidden Markov model, where condition-
ally on the latent states, the observations are not independent like it is the case for a regular
hidden Markov model. Instead, the current observation is allowed to depend on the previous
observation according to an autoregressive model of first order. As in an HMMmodel, the latent
states evolve according to a discrete first-order time homogeneous Markov model. We consider
data of n continuous random variables observed over time, each of potentially different lengths,
i.e., for each individual i = 1,2,…, n, we observe a vector yi;: ¼ ðyi,ui , …, yi,miÞ
T, with ui < mi.
Define u0 ¼ min
1 ≤ i ≤ n
uif g and M ¼ max
1 ≤ i ≤ n
mif g and note that the times ui and mi may vary over the
entire observation period from u0 to M with the restriction that ui – mi ≥ 1, for i = 1,2,…,n.
We assume, for i = 1,2,…,n for integer time t = ui,…,mi, that the random variable Yi,t taking
nonnegative values depends only on the states Xt and the previous observation Yi,t–1, and
based on the model developed by Farcomeni and Arima [10], we get the following model:
Yi, tjXt¼xt ¼ β
ðxtÞYi, t1 þ μ
ðxtÞ þ εi, t: (1)
The choice of the autoregressive part of the model is motivated by the fact that successive
biomarker observations are most of the time correlated from many diseases unlike the hypoth-
esis of independence between observations in HMMs.
We interpret x as the vector of the hidden health states of the patients; in the case of breast cancer,
those states would be localized or advanced metastatic breast cancer for example, while y is the
vector of the biomarkers observed and measured for the patients. The εi,t are normal variables
with mean 0 and variance σ2 such that εi,t and εi0,t0 are uncorrelated, (i, t) 6¼ (i
0, t0).
The parameters βðxtÞ and μðxtÞ are parameters taking values in R for each hidden state and
σ2 ∈ Rþ.
Similar to Ref. [13], the transition matrix of the Markov chain Π is time homogeneous with
dimension a  a where a is the number of hidden states, and Π = (Πgh, g = 1,…,a; h = 1,…,a)
whereΠgh = P(Xt = h|Xt–1 = g), for g = 1,2,…,a; h = 1,2,…, a; and t = u0+1,…,M. We let the first state
Xu0 to be selected from a discrete distribution with vector of probabilities r = (r1,…,ra). Also we
consider the time of initial observation ui, the initial observed state yi,ui , and the number of
consecutive time points that were observed mi – ui + 1. Let μ = (μ
(1),…, μ(a)), β = (β(1),…,β(a)), and
θ = (μ, β, σ2, r, Π) be the set of all parameters in the model. We suppose that the individuals, i.e.,
Yi,t, behave independently conditionally on X. Therefore, for i = 1,…,n, Pðyi;:jyi,ui , x,θÞ ¼
Ymi
t¼uiþ1
Pðyi, tjyi, t1, xt,ΘÞ and PðxjθÞ ¼ Pðxu0Þ
YM
t¼u0þ1
Pðxtjxt1,ΠÞ, where Pðxtjxt1,ΠÞ ¼ PðXt ¼
xtjXt1 ¼ xt1,ΠÞ ¼ Πxt1,xt : Then, the likelihood density for the observations of all individuals
y = (y1,…,yn) given first time vector of observations y0 ¼ ðy1;u1 ,…, yn,unÞ, x, and θ is
Pðyjy0, x,θÞ ¼
Yn
i¼1
Pðyi;:jyi,ui , x,θÞ,
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This is due to the conditional independence of the yi, given x and θ. The joint mass of each yi,.
and x given yui and θ can be written as follows: Pðyi;:, xjyi,ui ,θÞ ¼ Pðyi;:jyi,ui , x,θÞ  Pðxjyui ,θÞ:
Using the Markov property of the hidden process, we have after simplification Pðxjyi,ui ,θÞ
∝ Pðyi,ui jx,θÞPðxjθÞ ¼ Pðyi,ui jxui ,θÞrxu0Πxu0 ,xu0þ1 ⋯ΠxM1,xM : In addition, Pðyi;:jyi,ui , x,θÞ ¼Ymi
t¼uiþ1
Pðyi, tjyi, t1, x,θÞ, and consequently,
Pðyi;:, xjyi,ui ,θÞ ∝ rxu0Pðyi,ui jxui ,θÞ
YM
t¼u0þ1
Πxt1,xt
Ymi
t¼uiþ1
Pðyi, tjyi, t1, x,θÞ: Finally, under the hypoth-
esis of normal error distribution for the autoregressive parameters of the model (Eq. (1)) and
the Chapman-Kolmogorov property, the joint distribution of yi,. and x given yi,ui and θ can be
simplified to:
Pðyi;:, xjyi,uiθÞ∝Pðyi,ui jxui ,θÞ
Ya
h¼1
r
χ
xu0f g
ðhÞ
h
YM
t¼u0þ1
Ya
g¼1
Ya
h¼1
Πg,h
χ xt,xt1f g
ðg,hÞ

Ymi
t¼uiþ1
Ya
h¼1
1
σφ
yi, tμ
ðhÞβðhÞyi, t1
σ
  χ xtf gðhÞ
,
where φ denotes the density of a standard normal distribution N ð0; 1Þ and χ Af gðxÞ is the usual
indicator function of a set A. Finally, the joint distribution of y and x has the following form:
Pðy, xjy0,θÞ∝
Ya
h¼1
r
χ
xu0f g
ðhÞ
h
YM
t¼u0þ1
Ya
g¼1
Ya
h¼1
Πg,h
χ xt,xt1f g
ðg,hÞ

Yn
i¼1
Ya
l¼1
1
σφ
yi,ui
μðlÞ
σ
  χ xtf gðlÞ

Yn
i¼1
Ymi
t¼uiþ1
Ya
h¼1
1
σφ
yi, tμ
ðhÞβðhÞyi, t1
σ
  χ xtf gðhÞ
:
(2)
4. Bayesian estimation of the model parameters
We will use a Bayesian approach to estimate the model parameters. Inference in the Bayesian
framework is obtained through the posterior density, which is proportional to the prior multi-
plied by the likelihood. The posterior distribution for our model, as in most cases, cannot be
derived analytically, and we will approximate it through MCMC methods specifically
designed for working with the augmented likelihood with the hidden states. In fact, MCMC
methods start by specifying the prior density Π(θ) for the parameters. Since the data Y are
available, the general sampling methods work recursively by alternating between simulating
the full conditional distributions X given y and θ given x and y.
4.1. Prior distributions
Under the assumption of independence between the parameters θ ¼ ðμ, β, σ2, r,ΠÞ, the prior
density could be written as PðθÞ ¼ PðrÞPðΠÞPðμÞPðβÞPðσ2Þ. r is the parameters of a multino-
mial distribution; hence, the natural choice for the prior would be a Dirichlet distribution
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r  Dðα01,…,α0aÞ. Later on,
Xa
j¼1
Πij ¼ 1, and we assume that Πi  Dðδi1,…, δiaÞ for each row i
of the transition matrix. This choice of the Dirichlet prior can be even the default Dð1;…; 1Þ as
recently discussed in Ref. [18]. In fact, a Dirichlet prior is justified because the posterior density
of each row of the transition matrix is proportional to the density of a Dirichlet distribution,
and hence, choosing a Dirichlet prior would give a posterior Dirichlet. This can be justified as
follows for a given set of parameters λ ¼ ðλ1,…,λaÞ from a discrete or from a multinomial
density:
πðx1,…, xa,λ1,…,λaÞ ¼
n!
x1 !…xa!
λx11 …λ
xa
a for the nonnegative integers x1,…, xa, with
Xa
i¼1
xi ¼ n:
This probability mass function can be expressed, using the gamma function Γ, as
πðx1,…, xa,λ1,…,λaÞ ¼
Γ
Xa
i¼1
xiþ1
 !
Ya
i¼1
Γðxiþ1Þ
Ya
i¼1
λxii : This form shows its resemblance to the Dirichlet
distribution, and by starting from supposing the prior λ∝Dðα0,…,αaÞ, the posterior is
PðλjxÞ∝PðλÞPðxjλÞ∝
Y
i
λxii
Y
i
λαi1i ∝
Y
i
λxiþαi1i ∝Dðx1 þ α1,…, xa þ αaÞ:
Furthermore, concerning the priors for parameters of the autoregressive model, we suppose
for h ¼ 1;…, a: μðhÞ  N ðαh, τhÞ, β
ðhÞ  N ðbh, chÞ, and inverse gamma (IG) prior for σ
2  IG
ðε, ζÞ. αh, τh, bh, ch, E, ζ are hyperparameters to be specified. For more details on Bayesian
inference and prior selection in HMM, the reader is referred to Ref. [19]. In our case, prior
distributions for the autoregressive parameters were proposed by Ref. [20] for a mixture
autoregressive model, who points out that they are conventional prior choices for mixture
models.
4.2. Sampling the posterior distribution for the hidden states
Chib [21] developed a method for the simulation of the hidden states from the full joint
distribution for the univariate hidden Markov model case. We will describe his full Bayesian
algorithm for the univariate hidden Markov model before a generalization to our MAR(1)
HMM.
4.2.1. Chib’s algorithm for the univariate hidden Markov model for estimation of the states
Suppose we have an observed process Yn ¼ ðy1,…, ynÞ and the hidden states Xn ¼ ðx1,…, xnÞ,
θ are the parameters of the model. We adopt for simplicity Xt ¼ ðx1,…, xtÞ the history of the
states up to time t and Xtþ1 ¼ ðxtþ1,…, xnÞ the future from t + 1 to n. We use the same notation
for Yt and Y
t+1.
For each state xt ∈ 1; 2;…, af g for t ¼ 1; 2;…, n, the hidden model can be described by a condi-
tional density given the hidden states πðytjYt1, xt ¼ kÞ ¼ πðytjYt1,θkÞ, k ¼ 1;…, a, with xt
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depending only on xt–1 and having transition matrix Π and initial distribution Π0, and the
parameters for pi(.) are θ ¼ ðθ1,…,θaÞ.
Chib [21] shows that it is preferable to simulate the full latent data Xn ¼ ðx1,…, xnÞ from the
joint distribution of x1,…, xnjYn,θ, in order to improve the convergence property of the
MCMC algorithm because instead of n additional blocks if each state is simulated separately,
only one additional block is required. First, we write the joint conditional density as
PðXnjYn,θ,ΠÞ ¼ PðxnjYn,θÞPðxn1jYn, xn,θ,ΠÞ ⋯ Pðx1jYn, X
2,θ,ΠÞ:
For sampling, it is sufficient to consider the sampling of xt from PðxtjYn, X
tþ1,θ,ΠÞ. Moreover,
PðxtjYn, X
tþ1,θ,ΠÞ∝PðxtjYt,θ,ΠÞPðxtþ1jxt,ΠÞ. This expression has two ingredients: the first is
Pðxtþ1jxt,ΠÞ, which is the transition matrix from the Markov chain. The second is PðxtjYt,θ,ΠÞ
that would be obtained by recursively starting at t = 1.
The mass function Pðxt1jYt1,θ,ΠÞ is transformed into PðxtjYt,θ,ΠÞ, which is in turn
transformed into Pðxtþ1jYtþ1,θ,ΠÞ and so on. The update is as follows: for k ¼ 1;…, a, we
could write
Pðxt ¼ kjYt,θ,ΠÞ ¼
Pðxt ¼ kjYt1,θ,ΠÞpiðytjyt1,θkÞXa
l¼1
Pðxt ¼ ljYt1,θ,ΠÞpiðytjyt1,θlÞ
:
These calculations are initialized at t = 0, by setting Pðx1jY0,θÞ to be the stationary distribution
of the Markov chain. Precisely, the simulation proceeds for k ¼ 1;…, a, recursively by first
simulating Pðx1 ¼ kjY0,θÞ, from the initial distribution Π0(k) and Pðx1 ¼ kjY1,θ,ΠÞ
∝Pðx1 ¼ kjY0,θ,ΠÞpiðy1jY0,θkÞ: Then, we get by forward calculation Pðxt ¼ kjYt1,θÞ ¼Xa
l¼1
ΠlkPðxt1 ¼ ljYt1,θÞ, for each t ¼ 2;…, n, where Πlk is the transition probability and
Pðxt ¼ kjYt,θÞ∝Pðxt ¼ kjYt1,θ, PÞΠðytjYt1,θkÞ: The last term in the forward computation
Pðxn ¼ kjYn,θÞ would serve as a start for the backward pass, and we get recursively for each
t ¼ n 1;…; 1:; Pðxt ¼ kjYn, X
tþ1,θÞ∝PðxtjYt1,θ,ΠÞPðxtþ1jxt ¼ k,ΠÞ, which permits the
obtention of Xn ¼ ðx1,…, xnÞ.
4.2.2. Simulating the hidden states for the MAR(1)HMM
Returning to our model, and adopting notations and algorithm developed by Fitzpatrick and
Marchev, f will denote the observation density for the MAR(1)HMM, and for u0 < t < M;
xt ¼ ðxu0 ,…, xtÞ, x
t ¼ ðxt,…, xMÞ, yðtÞ ¼ ðyi, t, i ¼ 1; 2;…, nÞ, y, t ¼ ⋃
i:ui<t
yi,ui ,…, yi,min t,mif g
n o
,
and yt ¼ ⋃
i:t<mi
yi,max tþ1;uif g,…, yi,mi
n o
. The posterior distribution of the hidden state could be
written as: PðxMjy,M,θÞ ¼ PðxMjy,M,θÞ ⋯ Pðxu0 jy,M, x
u0þ1,θÞ. So we could sample the
whole sequence of states by sampling from Pðxtjy,M, x
tþ1,θÞ: Hence, the estimation of the
hidden states is performed recursively by first initializing
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Pðxu0 jy,u0 ,θÞ∝Pðy,u0 jxu0ÞPðxu0 jrÞ; y,u0 ¼ yi,ui, , ui ¼ u0, i ¼ 1;…, n
n o
:
Pðxu0þ1 ¼ kjy,u0 ,θÞ ¼
Xa
l¼1
ΠlkPðxu0 ¼ ljY,u0Þ; k ¼ 1;…, a:
Pðxu0þ1 ¼ kjy,u0þ1,θÞ∝Pðxu0þ1 ¼ kjy,u0 ,θÞf ðyðu0Þjy,u0 ,θkÞ:
We perform a similar calculation for every state at time t, and we conclude by calculating
PðxM ¼ kjy,M1,θÞ ¼
Xa
l¼1
ΠlkPðxM1 ¼ ljY,M1,θÞ, and PðxM ¼ kjy,M,θÞ∝PðxM ¼ kjy,M1,θ
Þf ðyðMÞjy,M1,θkÞ. Later on, we get PðxM ¼ kjy,M,θÞ, which permits the simulation of
PðxMjy,M,θÞ: Finally, by backward calculation, we simulate from the probabilities
Pðxtjy,M, x
tþ1,θÞ∝Pðxtþ1jxt,ΠÞPðxtjy, t,θÞ for each time t ¼ M 1;…, u0. Those backward
probabilities would permit the simulation of the latent states.
4.3. Sampling from P(θ|x, y)
4.3.1. Sampling Π
Under the prior assumption of Dirichlet prior for each row of the transition matrix
PðΠiÞ∝Dðδi1,…, δiaÞ, and the independence assumption between those rows, the posterior
distribution for Πi can be developed using Eq. (2) as follows: Let nij denote the number of
single transitions from state i to state j, so
PðΠijy, xÞ∝PðΠiÞ
YM
t¼u0þ1
Ya
j¼1
Π
χ xt1,xtf g
ði, jÞ
∝PðΠiÞ
Ya
j¼1
Π
nij
ij ∝
Ya
j¼1
Π
δijþnij1
ij
∝Dðδi1 þ ni1,…, δia þ niaÞ:
4.3.2. Sampling posterior distribution for initial distribution
Let n0l ¼ χxu0 ðlÞ, for l ¼ 1;…, a. Using (2), under Dirichlet prior Dðδ01,…, δ0aÞ for the parameter
r, we obtain Pðrjx, yÞ∝PðrÞ
Ya
l¼1
r
χ
xu0f g
ðlÞ
l ∝
Ya
l¼1
rδ0lþn0l1l ∝Dðδ01 þ n01,…, δ0a þ n0aÞ:
4.3.3. Sampling posterior distribution for the autoregressive parameters μ, β, σ2
When a complete conditional distribution is known such as the normal distribution or beta
distribution, we use the Gibbs sampler to draw the random variable. This is the case for our
model. Let us define nuiðlÞ ¼
Xn
i¼1
χ xui¼lf g
, nl ¼
Xn
i¼1
Xmi
t¼uiþ1
χ xt¼lf g, N ¼
Xa
l¼1
nl, n0l ¼ χ xu0f g
ðlÞ: So for
l ¼ 1; 2;…, a; by supposing N ðαl, τlÞ as prior distribution and using Eq. (2), the conditional
posterior distribution of μ(l) is:
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PðμðlÞjy, xÞ∝PðμðlÞÞ
Yn
i¼1
1
σφ
yi,ui
μðlÞ
σ
  χ
xuif g
ðlÞ

Yn
i¼1
Ymi
t¼uiþ1
1
σφð
yi, tμ
ðlÞβðlÞyi, t1
σ Þ
 χ xtf gðlÞ
:
∝ exp
1
2
ðμðlÞ  αlÞ
2
τl
þ
Xn
i¼1;xui¼l
yi,ui  μ
ðlÞ
σ
 !2
þ
Xn
i¼1
Xmi
t¼uiþ1;xt¼l
yi, t  μ
ðlÞ  βðlÞyi, t1
σ
 !28<
:
9=
;:
then μðlÞ=y, x  N ð~τ l, ~α lÞ with inverse mean ~τ l
1 ¼
nui ðlÞþnl
σ2
þ 1τl and variance
~α l ¼ ~τ l
Xn
i¼1;xui¼l
yi,ui þ
Xn
i¼1
Xmi
t¼uiþ1;xt¼l
ðyi, t  β
ðlÞyi, t1Þ
σ2
þ
αl
τl
0
BBBB@
1
CCCCA:
For βðlÞ, l ¼ 1;…, a, and similar to μ(l), N ðbl, clÞ was proposed as prior choice to obtain:
PðβðlÞjy, xÞ∝PðβðlÞÞ
Yn
i¼1
Ymi
t¼uiþ1
1
σ
φ
yi, t  μ
ðlÞ  βðlÞyi, t1
σ
 !" #χ xtf gðlÞ
,
and therefore, βðlÞ=y, x  N ð~cl,~b lÞ with inverse mean ~cl
1 ¼ 1cl þ
Xn
i¼1
Xmi
t¼uiþ1;xt¼l
y2
i, t1
σ2 and variance
~bl ¼ ~cl
bl
cl
þ
Xn
i¼1
Xmi
t¼uiþ1;xt¼l
ðyi, t  μ
ðlÞÞyi, t1
σ2
0
BBBB@
1
CCCCA:
For the posterior distribution of σ2, by supposing IGðε, ζÞ as prior, we deduce from Eq. (2)
Pðσ2jy, xÞ∝ ðσ2Þðεþ1Þ exp ð
ζ
σ2
Þ
Yn
i¼1
1
σ
φ
yi,ui  μ
ðxui Þ
σ
 !" #

Yn
i¼1
Ymi
t¼uiþ1
1
σ
φ
yi, t  μ
ðxtÞ  βðxtÞyi, t1
σ
 !" #
,
consequently σ2=y, x  IGð~ε, ~ζÞ with parameters ~ε ¼
nuiþ N
2 þ ε and
~ζ ¼
Xn
i¼1
ðyi,ui  μ
ðxui ÞÞ2 þ
Xn
i¼1
Xmi
t¼uiþ1
ðyi, t  μ
ðxtÞ  βðxtÞyi, t1Þ
2
2
þ ζ:
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Finally, the algorithm is ran for d = 1,…,D iterations by alternating between the following steps,
where in each step we compute a conditional posterior for the given parameter:
The MCMC algorithm:
1. For h ¼ 1; 2; ::::; a, give reference values for the hyperparameters αh, τh, ah, bh, δ0h, and δih
for i ¼ 1; 2; ::::; a:
2. Initialization (Step d = 1 of the MCMC iterations): Initialize Π(1), r(1), μ(1), β(1), and σ2(1).
3. Simulation of the hidden states:
a. Initialization of forward simulation: Pðx
ðdÞ
u0 jy,u0 ,θÞ∝Pðy,u0 jx
ðdÞ
u0 ÞPðx
ðdÞ
u0 jr
ðdÞÞ, with y,u0 ¼
yi,ui, , ui ¼ u0, i ¼ 1;…; n
n o
:
b. Forward simulation: For k ¼ 1;…:;a and t ¼ u0 þ 1;…:;M :
Pðx
ðdÞ
t ¼ kjy, t1,θÞ ¼
Xa
l¼1
Π
ðdÞ
lk Pðx
ðdÞ
t1 ¼ ljY, t1,θÞ and
Pðx
ðdÞ
t ¼ kjy, t,θÞ ¼
Pðx
ðdÞ
t ¼kjy, t1,θkÞf ðyðtÞjy, t1,θkÞXa
l¼1
Pðxdt¼ljy, t1,θÞf ðyðtÞjy, t1,θlÞ
.
c. Initialization of backward simulation: For k ¼ 1;…:;a, given
Pðx
ðdÞ
M ¼ kjy,M,θÞ from forward simulation, we get Pðx
ðdÞ
M jy,M,θÞ:
d. Backward simulation: For k ¼ 1;…:;a and t ¼ M 1;…;u0 :
Pðx
ðdÞ
t jy,M, x
tþ1ðdÞ,θÞ∝Pðx
ðdÞ
tþ1jx
ðdÞ
t ,πÞPðx
ðdÞ
t jy, t,θÞ:
4. Estimation of the initial distribution and the transition distribution
a. for l ¼ 1;…:;a, k ¼ 1;…:;a. Calculate n0l ¼ χ xðdÞu0f g
ðlÞ and nkl ¼ Σ
M
t¼u0þ1
χ
x
ðdÞ
t1
,xðdÞtf g
ðk, lÞ:
b. Sample ðr
ðdþ1Þ
1 ;…:;r
ðdþ1Þ
a Þ∝Dðδ01 þ n01;…:;δ0a þ n0aÞ:
c. For i ¼ 1;…:; a; sample ðΠ
ðdþ1Þ
i1 ;…:;Π
ðdþ1Þ
ia Þ∝Dðδi1þ ni1;…:;δiaþ niaÞ:
5. Simulation of μ: For l ¼ 1;…:; a,
a. ~τl
1 ¼
nui ðlÞþnl
σ2
ðdÞ
þ 1τl :
b. ~αl ¼ ~τl
Xn
i¼1;xui¼l
yi,ui
þ
Xn
i¼1
Xmi
t¼uiþ1;xt¼l
ðyi, tβ
ðlÞ
ðdÞ
yi, t1Þ
σ2
ðdÞ
þ αlτl
0
BBBB@
1
CCCCA
:
c. Simulate μ
ðlÞ
ðdþ1Þ=y, x  N ð~αl, ~τlÞ:
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6. Simulation of β: For l ¼ 1;…:;a,
a. ~cl
1 ¼ 1cl þ
Xn
i¼1
Xmi
t¼uiþ1;xt¼l
y2
i, t1
σ2
ðdÞ
:
b. ~bl ¼ ~cl
bl
cl
þ
Xn
i¼1
Xmi
t¼uiþ1;xt¼l
ðyi, tμ
ðlÞ
dþ1
Þyi, t1
σ2
ðdÞ
0
BBBB@
1
CCCCA
.
c. Simulate β
ðlÞ
ðdþ1Þ=y, x  N ð
~bl,~clÞ:
7. - Simulation of σ2:
a. ~E ¼
nuiþN
2 þ E.
b. ~ζ ¼
Xn
i¼1
ðyi,ui
μ
ðxui
Þ
ðdþ1Þ
Þ2þ
Xn
i¼1
Xmi
t¼uiþ1
ðyi, tμ
ðxtÞ
ðdþ1Þ
β
ðxtÞ
ðdþ1Þ
yi, t1Þ
2
2 þ ζ.
c. Simulate σ2ðdþ1Þ=y, x  IGðE,
~ζÞ.
5. Simulation study
In this section, we apply our results to the breast cancer model discussed earlier. The main
reason behind our work is that the progression of breast cancer cannot be seen directly unless
we use observations related to the disease that could characterize its progression; those obser-
vations here are quantities which could be measured; they are called biomarkers, where the
word biomarker is used to designate any objective indication of a biological process or disease
condition including during treatment and should be measurable. Furthermore, biomarkers are
increasingly used in the management of breast cancer patients. One example is reported in Ref.
[22], stating that there is correlation between elevation of CEA and/or CA15-3 and disease
progression, in breast cancer patients. Also we use the autoregressive dependence among the
observations to add more dynamics to the model unlike conventional HMMs where the
successive observations given the Markov process are independent. We used the classification
of breast cancer in three states: local where the disease is confined within the breast, the
regional phase when the lymph nodes are involved, and the distant stage where the cancer is
found in other parts of the body. We restrict ourselves to these three stages unlike other stage
classifications that divide the progression in more than three stages such as the TNM (tumor,
node, and metastasis) system. By lack of finding data about breast cancer biomarkers, we will
confine ourselves to simulate an MAR(1)HMM model for observation time M = 24, and a
number of individuals n = 210, a = 3 for Markov states number, with the length observation
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time for each individual selected uniformly between 2 and M. The simulation process sup-
poses we have for the autoregressive means μ ¼ ðμð1Þ,μð2Þ,μð3ÞÞ ¼ ð12; 24; 36Þ, since markers
such as CA15–3 increase as the disease advances toward metastatic breast cancer. In addition,
CA15–3 increase rapidly between successive observations, and thus, we take in the simulation
the parameters β ¼ ðβð1Þ, βð2Þ, βð3ÞÞ ¼ ð0:2; 0:4; 0:8Þ.
The algorithm of simulation works as follows:
1. For each individual i ¼ 1;…, n, choose mi the length of observation for that individual i.
2. Generate each discrete disease state xt using transition matrixΠ ¼ ð0:7; 0:2;0:1; 0:1; 0:6; 0:3;
0:2; 0:3; 0:5Þ for t ¼ u0þ1,…,M.
3. Generate the observations yi,t for all individuals using our model 1.
We choose a prior σ2  IGð0:001; 0:001Þ, a Dð1;…; 1Þ prior for each row of Π, and Gaussian
noninformative priors for the μs and the βs. Having the hidden states and the observations,
we ran our algorithm for 8000 MCMC iterations. MCMC algorithm convergence was
assessed by analyzing MCMC iterations mixing plots that are shown in Figure 1, autocorre-
lation sample graphs checking as illustrated in Figure 2, and inspecting histograms of poste-
rior densities for the parameters of the models in Figure 3. All parameters show good mixing
of chains, autocorrelations that decay immediately after a few lags, and perfect posterior
densities fitting. Also the Gelman [23] potential scale reduction factor (PSRF) was plot. The
PSRF is measured for more than two MCMC chains (three chains in this works are consid-
ered), and it is measured for each parameter of the model; it should show how the chains
have forgotten their initial values and that the output from all chains is indistinguishable. It is
based on a comparison of within-chain and between-chains variances and is similar to a
classical analysis of variance; when the PSRF is high (perhaps greater than 1.1 or 1.2), then
we should run our chains out longer to improve convergence to the stationary distribution.
Each PSRF declines to 1 as the number of iterations approaches infinity to confirm conver-
gence. All the parameters have shown a PSRF less than 1.1 as the number of iteration
increases and by the way a good sign of convergence (Figure 4). Moreover, we should point
out that in the family of Markov switching model there is the so-called label switching
problem (e.g., Ref. [24]) which arises identifiability problem, and hence, we would not
estimate perfectly the parameters. In addition, the posterior densities could show evidence
of multimodality. some authors postprocess the output of the MCMC to deal with the issue
(e.g., [25]), while other uses a random permutation of the parameters in each iteration of the
MCMC algorithm (e.g., [26]) or one can call for an invariant loss function method (e.g., [27]).
In our case, no identifiability issue is noticed since we used well-separated prior hyper-
parameters. Even when we start from different initial values for the parameters, our algo-
rithm converges immediately after a few iterations.
Finally and before giving our results, we should report that the simulation of the Dirichlet
posterior was carried out following ([28, p. 22], [29, p. 155]) who reported that the posterior
Dirichlet parameters should be simulated using the beta distribution approach. Table 1 shows
how the posterior values estimated from algorithm are very close to the true ones.
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Figure 1. Markov chain mixing for each parameter through MCMC algorithm simulation.
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Figure 2. Autocorrelation sample plots for parameters of the model.
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Figure 3. Posterior densities for the parameters of the model (after 8000 iterations).
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Figure 4. Potential scale reduction factor convergence to less than 1.02 with more iterations.
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6. Conclusion
We have extended the method of Chib [21] for block update estimation of the states to a MAR
(1)HMM model. Furthermore, we would like to point out that our model can easily be
extended to include missing observations, as we should only add an extra step in each MCMC
iteration to estimate the missing observations. Also, we can estimate the autoregressive model
for different values of the autoregressive order, p ≥ 1, by evaluating the Bayesian information
criterion to select the best order that fits the observations of the model. Our model would
capture the complexity and the dynamics of the evolution of breast cancer by introducing the
latent states; the probabilities of transition between the latent states allow to compare among
the effects of treatments on slowing or accelerating the transition of the disease from one health
stage to another the autoregressive parameter mean values corresponding to different stages of
the disease would guide medical doctors and scientists to monitor patients in different phases
of the disease. The model incorporates individual observations with different lengths.
Last but not least, we like to mention the utilities of switching diffusion processes in addres-
sing and analyzing many complicated applications such as in finance and risk management.
Our future work would be to apply these processes to explore disease progression, because
they are characterized by the coexistence of continuous dynamics and discrete events as well
as their interactions.
Parameter True value Posterior statistics
Mean Standard deviation Confidence interval (5%)
μ1 12 11.929 0.047 (11.851–12.005)
μ2 24 23.923 0.047 (23.847–24.000)
μ3 36 35.843 0.070 (35.729–35.959)
β1 0.2 0.2016 0.0012 (0.1997–0.2035)
β2 0.4 0.4018 0.0009 (0.4004–0.4032)
β3 0.8 0.8022 0.0010 (0.8005–0.8038)
π11 0.7 0.688 0.068 (0.5715–0.797)
π12 0.2 0.223 0.062 (0.129–0.332)
π13 0.1 0.090 0.042 (0.032–0.17)
π21 0.1 0.091 0.035 (0.041–0.154)
π22 0.6 0.607 0.059 (0.507–0.701)
π23 0.3 0.302 0.055 (0.214–0.397)
π31 0.2 0.153 0.053 (0.075–0.250)
π32 0.3 0.368 0.071 (0.257–0.488)
π33 0.5 0.479 0.073 (0.358–0.599)
σ2 2 2.023 0.032 (1.970–2.077)
Table 1. Posterior inference for the parameters of the MAR(1)HMM model.
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